Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
| ▸ | MGMT | P16455 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239504 | 0.82 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL17239478 | 0.81 | MGMT (0.31) | DGAT1MGMT | |
| SCHEMBL19953625 | 0.78 | DGAT1 (0.32) | DGAT1NPC1 | |
| SCHEMBL23306274 | 0.78 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL17239574 | 0.77 | PTGS2 (0.33) | PTGS2 | |
| SCHEMBL17253192 | 0.77 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL13871296 | 0.76 | F2RL1 (0.35) | DGAT1F2RL1NPC1 | |
| SCHEMBL4152078 | 0.76 | KLKB1 (0.37) | DGAT1F2RL1PTGS2NPC1 | |
| SCHEMBL25109623 | 0.75 | DGAT1 (0.34) | DGAT1F2RL1NPC1 | |
| SCHEMBL25413906 | 0.74 | DGAT1 (0.33) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6534505-B2 | Cognition activators, treatment of Alzheimer's disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| US-6448249-B1 | Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands | MERCK SHARP & DOHME LTD. (GB) | 2002-09-10 | — | — | US | disclosed |
| US-6440967-B1 | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-20010049439-A1 | Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | DGAT1 3635/4885HSD11B1 3941/4885F2RL1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.